PT2243829E - Anticorpo anti-integrina-alfa9 humana humanizado melhorado - Google Patents

Anticorpo anti-integrina-alfa9 humana humanizado melhorado Download PDF

Info

Publication number
PT2243829E
PT2243829E PT97009047T PT09700904T PT2243829E PT 2243829 E PT2243829 E PT 2243829E PT 97009047 T PT97009047 T PT 97009047T PT 09700904 T PT09700904 T PT 09700904T PT 2243829 E PT2243829 E PT 2243829E
Authority
PT
Portugal
Prior art keywords
humanized anti
integrin antibody
improved humanized
human alpha9
alpha9
Prior art date
Application number
PT97009047T
Other languages
English (en)
Inventor
Toshihiro Nakashima
Kenji Uehara
Hirofumi Higuchi
Daisuke Ishikawa
Nobuchika Yamamoto
Hirotada Fujita
Fumihiko Sakai
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PT2243829E publication Critical patent/PT2243829E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT97009047T 2008-01-11 2009-01-09 Anticorpo anti-integrina-alfa9 humana humanizado melhorado PT2243829E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008004975 2008-01-11
JP2008282496 2008-10-31

Publications (1)

Publication Number Publication Date
PT2243829E true PT2243829E (pt) 2014-10-24

Family

ID=40853174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97009047T PT2243829E (pt) 2008-01-11 2009-01-09 Anticorpo anti-integrina-alfa9 humana humanizado melhorado

Country Status (21)

Country Link
US (2) US8603476B2 (pt)
EP (2) EP2243829B1 (pt)
JP (2) JP5440179B2 (pt)
KR (1) KR101634636B1 (pt)
CN (1) CN101918549B (pt)
AU (1) AU2009203369B2 (pt)
BR (1) BRPI0905656B8 (pt)
CA (1) CA2711882C (pt)
CY (1) CY1115897T1 (pt)
DK (1) DK2243829T3 (pt)
ES (1) ES2519047T3 (pt)
HR (1) HRP20141110T1 (pt)
IL (1) IL206898A (pt)
MX (1) MX2010007515A (pt)
PL (1) PL2243829T3 (pt)
PT (1) PT2243829E (pt)
RU (1) RU2503720C2 (pt)
SI (1) SI2243829T1 (pt)
TW (1) TWI432453B (pt)
WO (2) WO2009088065A1 (pt)
ZA (1) ZA201004770B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102333791B (zh) * 2009-03-10 2014-06-25 株式会社遗传科技 人源化k33n单克隆抗体的生成、表达和表征
WO2011004847A1 (ja) * 2009-07-07 2011-01-13 一般財団法人化学及血清療法研究所 新規ヒト化抗ヒトα９インテグリン抗体
JP6258194B2 (ja) * 2011-05-06 2018-01-10 ネックスヴェット オーストラリア プロプライエタリー リミテッド 抗神経成長因子抗体並びに前記の製造及び使用方法
AU2012322445B2 (en) * 2011-10-13 2016-12-15 Nexvet Australia Pty Ltd Canine/feline CD20 binding epitope and compositions for binding thereto
JP2021008406A (ja) * 2017-09-29 2021-01-28 アステラス製薬株式会社 改良型ヒト化抗ヒトα９インテグリン抗体含有医薬組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
KR100337069B1 (ko) 1993-03-11 2002-10-11 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 항-hiv모노클로날항체
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6939855B2 (en) 1997-07-31 2005-09-06 Elan Pharmaceuticals, Inc. Anti-inflammatory compositions and method
BR0208809A (pt) 2001-04-05 2004-03-09 Immuno Biolog Labiratories Co Anticorpo de anti-osteopontina, agente terapêutico para tratar doenças autoimunes, método e kit de detecção de anormalidades inflamatórias e uso do anticorpo
RU2305111C2 (ru) 2001-09-25 2007-08-27 Джуридикэл Фаундейшн Дзе Чемо-Серо-Терапьютик Рисерч Инститьют Рекомбинантное антитело против остеопонтина и его применение
WO2004001384A2 (en) * 2002-06-25 2003-12-31 The Regents Of The University Of California Methods for inhibiting angiogenesis, cell migration, cell adhesion, and cell survival
HUE058817T2 (hu) 2004-09-03 2022-09-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
JP4871740B2 (ja) * 2005-01-13 2012-02-08 株式会社ジーンテクノサイエンス 抗α９インテグリン抗体とその用途
BRPI0711229A2 (pt) 2006-05-31 2013-01-08 Astellas Pharma Inc anticorpo humanizado da osteopontina anti-humana, polinucleotÍdeo, vetor de expressço, cÉlula hospedeita, mÉtodo para produzir um anticorpo humanizado de osteopontina anti-humana, fÁrmaco terapÊutico, mÉtodo para prevenir ou tratar doenÇa autoimune e uso do anticorpo humanizado de oesteopontina anti-humana
JP4841326B2 (ja) 2006-06-20 2011-12-21 三菱電機株式会社 ホームネットワークシステム
EP2048163A4 (en) 2006-07-12 2010-07-21 Gene Techno Science Co Ltd ALPHA-9 HUMAN ANTI-INEGRIN ANTIBODY AND USE THEREOF
JP2008282496A (ja) 2007-05-11 2008-11-20 Konica Minolta Opto Inc 光ピックアップ装置
JP2007302676A (ja) * 2007-05-29 2007-11-22 Genentech Inc ヒト化抗β７アンタゴニストおよびその使用

Also Published As

Publication number Publication date
BRPI0905656B8 (pt) 2021-05-25
JPWO2009088064A1 (ja) 2011-05-26
RU2010133550A (ru) 2012-02-20
AU2009203369A1 (en) 2009-07-16
JPWO2009088065A1 (ja) 2011-05-26
KR20100110852A (ko) 2010-10-13
EP2243829A1 (en) 2010-10-27
CN101918549A (zh) 2010-12-15
RU2503720C2 (ru) 2014-01-10
US8603476B2 (en) 2013-12-10
WO2009088065A1 (ja) 2009-07-16
TWI432453B (zh) 2014-04-01
CN101918549B (zh) 2012-11-28
BRPI0905656B1 (pt) 2020-03-31
CA2711882C (en) 2016-07-19
IL206898A (en) 2015-06-30
ZA201004770B (en) 2011-03-30
JP5440179B2 (ja) 2014-03-12
CY1115897T1 (el) 2017-01-25
SI2243829T1 (sl) 2014-11-28
DK2243829T3 (da) 2014-11-17
ES2519047T3 (es) 2014-11-06
IL206898A0 (en) 2010-12-30
AU2009203369B2 (en) 2014-04-03
EP2243829A4 (en) 2012-05-23
WO2009088064A1 (ja) 2009-07-16
BRPI0905656A2 (pt) 2015-07-07
EP2239323A1 (en) 2010-10-13
TW200932759A (en) 2009-08-01
CA2711882A1 (en) 2009-07-16
KR101634636B1 (ko) 2016-06-29
US20110014193A1 (en) 2011-01-20
US20110059077A1 (en) 2011-03-10
EP2239323A4 (en) 2012-05-23
MX2010007515A (es) 2010-11-12
BRPI0905656A8 (pt) 2017-05-09
HRP20141110T1 (hr) 2015-01-16
PL2243829T3 (pl) 2015-04-30
EP2243829B1 (en) 2014-08-20

Similar Documents

Publication Publication Date Title
ZA201005348B (en) Humanized anti-c5ar antibodies
IL239947A0 (en) Monoclonal antibodies against 21-il of human origin
EP2349331A4 (en) HUMANIZED ANTIBODIES TO IL-6
EP2331579A4 (en) MONOCLONAL ANTIBODIES
ZA201004752B (en) Humanized anti-human nkg2a monoclonal antibody
IL204835A0 (en) Humanized antibody
SG10201601279SA (en) Monoclonal Antibody STRO-4
ZA201008993B (en) Anti-human interleukin-20 antibodies
IL217919A0 (en) Humanized anti-cdcp1 antibodies
PL2262831T4 (pl) Przeciwciała przeciwko properdynie
HK1168871A1 (zh) 單克隆抗體
HK1184470A1 (zh) 抗人 抗體
IL199974A0 (en) Humanized antibodies against cxcr3
ZA201004770B (en) Improved humanized anti-human x9-integrin antibody
GB0804686D0 (en) Humanized antibody
GB0804687D0 (en) Humanized antibody
GB0804684D0 (en) Humanized antibody
TWI348915B (en) Anti-vegf monoclonal antibody
GB0706965D0 (en) Humanized antibody
GB0706964D0 (en) Humanized antibody
GB0706963D0 (en) Humanized antibody